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Key questions
What is already known?
 ► Given the large burden of moderate acute malnutri-
tion (MAM, 34 million children affected each year) 
and risk of progression to more life-threatening con-
ditions without adequate treatment, the manage-
ment of MAM should be considered a public health 
priority.
 ► The cost and cost-effectiveness of MAM treat-
ment with new dietary supplements has not been 
assessed, but such evidence is needed to in-
form resource allocation for global child survival 
interventions.
What are the new findings?
 ► Using data from a cluster-randomised trial and a 
decision tree model, we estimated the long-term 
outcomes and incremental cost-effectiveness ratios 
comparing the health and economic outcomes of 
four dietary supplements.
 ► Our results show that providing MAM treatment is 
cost-effective across a wide range of cost-effective-
ness thresholds, and that despite having the highest 
per-unit food costs, the provision of ready-to-use 
supplementary food was the optimal dietary supple-
ment for MAM treatment, when compared with three 
other supplementary food options.
What do the new findings imply?
 ► MAM treatment could reduce the number of child 
deaths by 187 000 each year, and in settings with 
available resources, MAM treatment should be con-
sidered a cost-effective extension of existing child 
survival interventions.
AbsTrACT
Introduction Moderate acute malnutrition (MAM) causes 
substantial child morbidity and mortality, accounting for 
4.4% of deaths and 6.0% of disability-adjusted life years 
(DALY) lost among children under 5 each year. There is 
growing consensus on the need to provide appropriate 
treatment of MAM, both to reduce associated morbidity 
and mortality and to halt its progression to severe acute 
malnutrition. We estimated health outcomes, costs and 
cost-effectiveness of four dietary supplements for MAM 
treatment in children 6–35 months of age in Mali.
Methods We conducted a cluster-randomised MAM 
treatment trial to describe nutritional outcomes of four 
dietary supplements for the management of MAM: 
ready-to-use supplementary foods (RUSF; PlumpySup); 
a specially formulated corn–soy blend (CSB) containing 
dehulled soybean flour, maize flour, dried skimmed milk, 
soy oil and a micronutrient pre-mix (CSB++; Super Cereal 
Plus); Misola, a locally produced, micronutrient-fortified, 
cereal–legume blend (MI); and locally milled flour (LMF), 
a mixture of millet, beans, oil and sugar, with a separate 
micronutrient powder. We used a decision tree model to 
estimate long-term outcomes and calculated incremental 
cost-effectiveness ratios (ICERs) comparing the health and 
economic outcomes of each strategy.
results Compared to no MAM treatment, MAM treatment 
with RUSF, CSB++, MI and LMF reduced the risk of death 
by 15.4%, 12.7%, 11.9% and 10.3%, respectively. The 
ICER was US$9821 per death averted (2015 USD) and 
US$347 per DALY averted for RUSF compared with no 
MAM treatment.
Conclusion MAM treatment with RUSF is cost-effective 
across a wide range of willingness-to-pay thresholds.
Trial registration NCT01015950.
InTroduCTIon
It is estimated from survey data that 34 million 
children <5 years of age suffer from moderate 
acute malnutrition (MAM) and an additional 
16 million children suffer from severe acute 
malnutrition (SAM).1 The risk of associated 
morbidity and mortality increases with the 
severity of malnutrition, but both MAM and 
SAM impair immune function, increase the 
incidence and duration of common child-
hood infections, and heighten the risk of 
mortality.2 Compared with non-malnourished 
children, the rate of death is 3 times greater 
among children with MAM and 11 times 
greater among children with SAM.3 Given 
the large burden of MAM and possibility of 
progression to more life-threatening condi-
tions such as SAM without adequate support, 
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there is increasing recognition that the management of 
MAM should be considered a public health priority.
In response to concern regarding the limited effec-
tiveness of conventional approaches in the manage-
ment of MAM usually including a premix of blended 
food or cereal flour, other dietary supplements have 
been considered, including the use of ready-to-use foods 
and improved formulations of fortified blended flours.4 
Ready-to-use foods have been shown to be highly effec-
tive in the treatment of SAM5–7 and are increasingly used 
in the treatment and prevention of MAM,8–11 but their 
high cost raises questions regarding their long-term 
sustainability given the large global burden of MAM. New 
formulations of fortified blended flours with improved 
nutritional profiles may be a less expensive alternative for 
large-scale programmes, but rigorous scientific evidence 
to support their use remains limited.12–14
In 2010, a cluster-randomised trial was conducted to 
assess the effectiveness of four dietary supplements in 
the management of MAM among young children treated 
at outpatient health facilities in rural Mali.15 As part of 
this trial, we estimated the costs and cost-effectiveness of 
the four dietary supplements in terms of cost per death 
averted and per disability-adjusted life years (DALYs) 
averted.
MeTHods
We undertook an incremental cost-effectiveness analysis 
within a cluster-randomised trial designed to assess the 
effectiveness of four dietary supplements in the manage-
ment of MAM. The trial was conducted from May 2010 
to August 2011 in the Dioila Health District of Mali. 
Details of the trial design are presented elsewhere.15 In 
brief, 12 community health centres were randomised 
to provide one of four dietary supplements containing 
500 kcal/day: (1) ready-to-use supplementary foods 
(RUSFs, PlumpySup; Nutriset, France): a ready-to-use soy 
protein, peanut paste enriched with a vitamin–mineral 
complex; (2) CSB++: a specially formulated corn–soy 
blend containing dehulled soybean flour, maize flour, 
dried skimmed milk, soy oil and a micronutrient pre-mix 
(Super CerealPlus, Michiels Fabrieken, Belgium); (3) 
Misola (MI): a locally produced, micronutrient-fortified, 
cereal-legume blend containing millet or maize, soy and 
peanut flour (Misola, Mali); or (4) locally milled flour 
mixture (LMF): a mixture of home-available foods, 
including millet, beans, oil and sugar, as is currently 
recommended by the national treatment protocol for 
acute malnutrition16 when specially processed foods are 
not available, as well as a 1 g sachet of a multiple micronu-
trient powder (MixMe; DSM, South Africa) to be added 
after cooking.
Study villages (n= 95) received community-based 
screening for acute malnutrition (MAM or SAM) every 
2 months. Children 6–35 months of age and identified 
with MAM during screening, defined in the trial using 
either the 2006 WHO growth standards (−3≤weight 
for length Z-score [WLZ] <−2 or 11.5 cm≤mid upper 
arm circumference [MUAC] <12.5 cm) or the national 
protocol at the time of the study16 (70%≤National Center 
for Health Statistics weight-for-length median<80% or 11 
cm≤MUAC<12 cm), were referred to the nearest commu-
nity health centre where study eligibility was confirmed.
All children received standard care according to the 
national protocol for the community-based manage-
ment of MAM. Systematic treatment, including high-
dose vitamin A capsule and antihelminthic treatment, 
were provided on admission, as well as any specific treat-
ment required for malaria or other acute infections. The 
dietary supplements were distributed during clinic visits 
scheduled on a weekly basis for the first 4 weeks and 
biweekly thereafter for 12 weeks. At each scheduled visit, 
children received a physical examination and anthropo-
metric assessment using standard techniques. Children 
found to have developed SAM (defined as MUAC <11.5 
cm or WLZ <−3) or requiring inpatient care were referred 
to the nearest therapeutic feeding programme (TFP) or 
hospital, respectively, for treatment.
Costs and costing assumptions
Costs were assessed from the perspective of the health-
care provider. An ingredients approach17 was used to 
identify and cost all resources required for the two prin-
cipal activities in the community-based management of 
MAM: bimonthly community-based screening and MAM 
treatment. Each activity was composed of four cost cate-
gories: personnel; supplementary food; medical supplies 
and materials; infrastructure and logistical support. For 
each category, we created a cost inventory and quantified 
resources used throughout the course of treatment.
For the community-based screening activity, we calcu-
lated the costs of screening per child as the cost of 
conducting bimonthly community-based screening for 
1 year divided by the number of children with SAM or 
MAM detected in the same period, to avoid issues of 
seasonality in case detection. For the MAM treatment 
activity, total treatment costs were calculated as the sum 
of infrastructure costs per child and recurrent costs 
(including personnel, supplementary food, and medical 
supplies and materials) per enrolment or follow-up visit, 
where recurrent costs per follow-up visit were multiplied 
by the number of follow-up visits by arm. The analysis 
considered supplementation for MAM treatment to 
continue until the child experienced one of five MAM 
treatment outcomes: recovery, defined as attaining WLZ 
>−2.0 and MUAC >12.5 cm on at least two consecutive 
follow-up visits; default, defined as missing two consecu-
tive follow-up visits; non-response, defined as not meeting 
the criteria for recovery at 12 weeks; development of SAM 
and transfer to TFP or hospital; death.
Costs were estimated for a standard programme based 
on review of financial documents from the trial and key 
informant interviews at the Dioila Health District. These 
interviews were used to elicit estimates of resource use 
required if the programme for management of MAM was 
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Table 1 Costing analysis of community-based screening and treatment of acute malnutrition in Mali
Activity
Cost per child 
(2015 USD)
% of activity 
total Comments
1. Community-based screening
  Personnel 1.46 77% Includes stipend for 2 community volunteers, 1 day per village per screening
  Infrastructure and 
logistical support
0.26 14% Includes basic furniture (table and chairs) and MUAC bands
  Management and 
administration
0.17 9% 10% of direct costs29
Total* 1.89 100% 1766 children were identified with MAM or SAM
2. MAM treatment† 
  Personnel 8.30 22%–30% Includes 1 nurse (20 min) and 1 nurse assistant (10 min); US$1.66 per visit
  Infrastructure 6.46 17%–23% Includes semipermanent building with 1 storekeeper, 1 guard and 1 cleaner, 
anthropometric equipment (scale, height board and MUAC bands), furniture 
(consultation table, desk, chairs, benches and water container), medical 
equipment for physical examination (stethoscope, thermometer and otoscope), 
enrolment register, equipment and printed communication tools for cooking 
demonstrations
  Medical supplies and 
materials
2.67 7%–10% Includes vitamin A, deworming tablet, iron-folic acid, rapid malaria test, malaria 
treatment, and beneficiary card at enrolment and a disposable tongue depressor 
at each visit
Supplementary foods 
  RUSF 17.25 45% US$3.45 per weekly ration, includes food costs and domestic and international 
transport
  CSB++ 8.10 29% US$1.62 per weekly ration, includes food costs and domestic and international 
transport
  Misola 7.85 28% US$1.57 per weekly ration, includes food costs and domestic and international 
transport
  LMF 8.50 30% US$1.70 per weekly ration, includes food costs and domestic and international 
transport
Management and 
administration
2.52–3.46 9% 10% of direct costs29
Total 27.76–38.10 100%
3. SAM treatment 
  Direct cost per child 
treated
120.33 73% Includes personnel, therapeutic food, medical supplies and materials, 
infrastructure and logistic support for outpatient care and inpatient care30
  Management and 
administration
44.79 27% 37% of direct costs30
Total 165.12 100%
*When considering SAM treatment only, community-based screening would cost 14.51 per SAM child identified, including US$11.19 for personnel, US$2.00 for 
infrastructure and logistical support, and US$1.32 for management and administration with 231 children identified with SAM.
†Total costs of MAM treatment were calculated for 5 weeks of follow-up because the mean time to recovery was between 4 and 5 weeks for all four dietary 
strategies (table 2).
CSB, corn–soy blend; LMF, locally milled flour; MAM, moderate acute malnutrition; MUAC, mid upper arm circumference; RUSF, ready-to-use supplementary food; 
SAM, severe acute malnutrition.
implemented by government counterparts. All costing 
assumptions are presented in detail in online supplemen-
tary appendix 1 and table 1.
Model structure and transition probabilities
We used a decision tree model to compare the four 
dietary supplements examined in the trial with a hypo-
thetical alternative of providing treatment for SAM only 
(figure 1). For the four dietary supplements considered 
for MAM treatment, the probability of each treatment 
outcome (recovery, default, non-response, transfer to 
TFP or hospital) was based on the observed outcomes 
of the 1264 children enrolled in the trial (table 2). As 
the number of transfers to TFP or hospital observed 
in the trial was small (n=4), we assumed no group-wise 
differences in the number of hospitalisations. Transition 
probabilities not observed in the trial, including outcomes 
of untreated MAM, were taken from the published liter-
ature (table 2).
Analysis
We used the decision tree model to estimate costs 
incurred, probability of death and number of DALYs 
averted (see online supplementary appendix 1). We 
assumed that individuals alive at the end of 1 year faced 
the same age-specific mortality risks as the general popu-
lation. We calculated DALYs averted for one strategy 
compared with another as the difference in discounted 
life expectancy achieved by each strategy.
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Figure 1 Schematic of decision tree model. MAM, moderate acute malnutrition; SAM, severe acute malnutrition.
For each treatment pathway, the expected costs and 
effects were calculated using the probability of each treat-
ment outcome observed in the trial or estimated from 
the relevant literature. Dominated strategies, which were 
defined as those that were associated with higher costs 
and worse outcomes compared with one or a combination 
of strategies, were identified and removed from consid-
eration. Incremental cost-effectiveness ratios (ICERs) 
were then calculated among non-dominated strategies 
as the ratio of expected incremental costs and expected 
incremental effects for one strategy compared with 
the next least expensive. ICERs can be compared with 
external estimates of cost-effectiveness thresholds, with 
the optimal intervention being the intervention with the 
highest ICER that is less than the external threshold.18 19
Probabilistic sensitivity analysis (PSA) is used to under-
stand how the combined uncertainty in the parameters 
of an analysis produce uncertainty in final results.20 PSA 
was conducted using probability distributions defined for 
each model parameter (table 1) generated with 10 000 
simulations and assuming all parameters to be uncor-
related.21 When distributions for parameters could not 
be estimated from the trial data or relevant literature, we 
set the SD for the distribution equal to 50% of the mean, 
such that an equal-tailed 95% interval would be approx-
imately ±100% of the mean. Cost-effectiveness accept-
ability curves were plotted to identify the probability 
that a given strategy was the most cost-effective option 
over a range of willingness-to-pay values (i.e. the value 
below which providing a service is deemed cost-effective, 
equivalent to the cost-effectiveness threshold commonly 
defined by a country’s per capita Gross Domestic Product 
[GDP]).19 One-way sensitivity analyses were conducted 
for all key parameters to show the relative influence of 
single parameters on the estimated ICERs and presented 
as a tornado diagram. Sensitivity analyses varied each cost 
parameter by ±50%, the discount rate used in the calcu-
lation of the DALY from 0% to 5%, and all other model 
parameters from the 25th to the 97th percentiles of their 
probability distribution (table 2). In an additional sensi-
tivity analysis, we considered a ‘do nothing’ scenario in 
which no screening occurred and neither SAM nor MAM 
treatment was available. While this hypothetical scenario 
is inconsistent with WHO guidance that supports the 
community-based management of acute malnutrition, 
it is representative of many resource-limited settings. In 
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Table 2 Parameter values for decision tree model
Parameter Base Case Distribution
Range for one-
way sensitivity 
analysis
  Natural history
  Annual background mortality rate for non-wasted children 1-5y in 
Mali23 31
1.7% Beta: α=114, β=6556 1.4–2.0%
  DALY lost due to death from MAM or SAM32 27.8 Fixed 19–60
  Proportion of malnutrition cases with SAM15 13.1% Beta: α=3, β=20* 2.9–29%
  Probability of developing SAM among children with MAM33 9.3% Beta: α=4, β=39* 3.0–19.5%
  HR of mortality among children with untreated MAM3 3.4 Log-normal: μ=1.2, σ=0.09 2.8–4.0%
  HR of mortality among children with untreated SAM3 11.6 Log-normal: μ=2.45, σ=0.09 9.7–13.8%
  Duration of untreated SAM episode (weeks)34 20.2 Log-normal: μ=2.98, σ=0.22 12.8–30.3
  Duration of untreated MAM episode (weeks)34 11.6 Log-normal: μ=2.45, σ=0.08 10.0–13.4
  HR of mortality among children post-recovery35 1.2 Log-normal: μ=0.18, σ=0.18*,† 1–1.6
  SAM treatment
  Duration of SAM treatment (weeks)36 6.3 Log-normal: 1.8, 0.3 3.0–11.0
  Probability of defaulting from SAM treatment programme37 8.0% Beta:α=4, β=46* 2.3–16.9%
  Weight for calculating average of the duration of SAM and MAM 
among defaulters (higher weight assumes defaulters are more like 
recovered children; lower weight assumes defaulters are more like 
untreated children)
50% Beta: α=1, β=1* 2.5–97.5%
  MAM treatment arm in parent trial
  RUSF Treatment
  Probability of recovering from MAM after RUSF treatment 69.9% Beta: α=234, β=101 64.8–74.5%
  Probability of defaulting from RUSF treatment 6.6% Beta: α=22, β=313 4.2–9.5%
  Average Weeks to recovery 4.3 Weibull: shape=1.3, scale=4.6 0.3–12.9
  Average Weeks to default 5.7 Weibull: shape=2.2, scale=6.5 1.2–12.0
  CSB++Treatment
  Probability of recovering from MAM after CSB++treatment 61.1% Beta: α=209, β=133 55.9–66.2%
  Probability of defaulting from CSB++treatment 4.1% Beta: α=14, β=328 2.3–6.4%
  Average Weeks to recovery 4.2 Weibull: shape=1.2, scale=4.4 0.2–13.1
  Average Weeks to default 5.0 Weibull: shape=1.8, scale=5.6 0.7–11.9
  MI Treatment
  Probability of recovering from MAM after MI treatment 57.2% Beta: α=175, β=131 51.6–62.6%
  Probability of defaulting from MI treatment 7.8% Beta: α=24, β=282 5.1–11.1%
  Average Weeks to recovery 4.7 Weibull: shape=1.2, scale=5.0 0.3–14.6
  Average Weeks to default 4.0 Weibull: shape=1.4, scale=4.4 0.3–11.3
  LMF Treatment
  Probability of recovering from MAM after LMF treatment 57.7% Beta: α=162, β=119 51.8–63.4%
  Probability of defaulting from LMF treatment 1.1% Beta: α=3, β=281 0.2–2.9%
  Average Weeks to recovery 4.8 Weibull: shape=1.2, scale=5.1 0.2–15.6
  Average Weeks to default 9.4 Weibull: shape=7.84, scale=9.9 6.3–11.7
  Adverse Events
  Probability of incident SAM/hospitalisation during MAM treatment 0.4% Beta: α=5, β=1264 0.1–0.8%
  Average weeks to hospitalisation or SAM 6.3 Weibull: shape 1.2, sigma 6.6 0.3–19.7
*Distribution set so that SD is 50% of the mean such that the 95% interval will be approximately ±100% of the mean.
†Hazard ratios were set to equal the maximum of one or the random draw from the log-normal distribution such that the post-recovery probability of 
death would not be less than the background mortality.
CSB, corn–soy blend; DALY, disability-adjusted life year; LMF, locally milled flour; MAM, moderate acute malnutrition; MI, Misola; RUSF, ready-to-
use supplementary food; SAM, severe acute malnutrition.
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Table 3 Incremental outcomes and cost-effectiveness ratios for competing treatment strategies
Strategy
Average cost 
per child 
identified (US$)
Probability of 
death at 1 year for 
a child presenting 
with MAM (%)
Discounted life 
expectancy for a 
child presenting 
with MAM (years)
Incremental cost 
per death averted
Incremental cost 
per DALY averted
Treat SAM only 36.96 3.42 26.85 Referent Referent
Treat MAM with RUSF 89.01 2.89 27.00 US$9820.75 US$347.00
Treat MAM with CSB++ 90.43 2.99 26.97 Dom. Dom.
Treat MAM with MI 90.86 3.01 26.96 Dom. Dom.
Treat MAM with LMF 99.91 3.06 26.95 Dom. Dom.
Dom. indicates that a strategy was dominated by another strategy (or combination of strategies) being considered.
CSB, corn–soy blend; DALY, disability-adjusted life year; LMF, locally milled flour; MAM, moderate acute malnutrition; MI, Misola; RUSF, 
ready-to-use supplementary food; SAM, severe acute malnutrition.
the ‘do nothing’ scenario, children with untreated SAM 
could either recover or die. Children with MAM could 
remain with MAM and either recover spontaneously 
and survive or die, or progress to SAM. All analyses were 
conducted using TreeAge Pro 2013 (TreeAge Software, 
Williamstown, Massachusetts, USA) and STATA V.14.2 
(StataCorp, College Station, Texas, USA).
resulTs
Health outcomes
Progression to SAM at 1 year was estimated to be 8.1% 
without MAM treatment and 0.3% with MAM treatment. 
The 1-year risk of death for untreated MAM (‘Treat SAM 
only’) was 3.59% (table 3). Compared to SAM treatment 
only, MAM treatment with RUSF, CSB++, MI and LMF 
reduced the risk of death by 0·53 (95% CI: -0·08, -1·03), 
0·43 (95% CI: -0·01, -0·92), 0·41 (95% CI: 0·03, -0·88), 
and 0·35 (95% CI: 0·10, 0·82) percentage points (15·4%, 
12·7%, 11·9%, and 10·3%), respectively.
Costs
For the average 5-week course of supplementation observed 
in the trial, supplementary foods represented 28%–45% 
of total MAM treatment costs (table 1). Personnel was an 
important contributor to total MAM treatment costs (22%–
30%), while routine medical supplies and materials were 
less important (7%–10% of total MAM treatment costs). 
Community-based screening costs constituted only 4.7% of 
costs for the ‘Treat SAM only’ arm and 1.7%–1.9% costs for 
the MAM treatment arms.
Cost-effectiveness
For all cost-effectiveness outcomes, the CSB++, MI and 
LMF strategies were dominated, for example, they were 
associated with worse outcomes and higher costs. RUSF was 
estimated to have an ICER of US$9821 per death averted 
and US$347 per DALY averted, as compared with the 
‘Treat SAM only’ strategy. In a context where RUSF is not 
available, the ICERs for CSB++, MI and LM compared with 
‘Treat SAM only’ were $12,435, $13,146, and $17,486 per 
death averted and $446, 490, and 630 per DALY averted, 
respectively.
The ‘Treat SAM only’ strategy was most likely to be 
cost-effective up to a willingness-to-pay of US$347 per DALY 
averted (figure 2). At higher willingness-to-pay values, addi-
tional MAM treatment with RUSF was the preferred option 
and had a 56% probability of being the optimal strategy 
at a willingness-to-pay of US$732 (equal to the Mali gross 
domestic product [GDP] per capita in 2015). At this will-
ingness-to-pay value equal to the Mali GDP per capita in 
2015, the ‘Treat SAM only’ strategy had just a 4.0% proba-
bility of being the optimal strategy. The probability of the 
CSB++, MI or LMF strategies being the optimal strategy 
under any willingness-to-pay value was less than 22%, 16% 
and 6%, respectively.
sensitivity analyses
Average time to recovery in the RUSF arm was a major 
source of uncertainty; however, compared with the ‘Treat 
SAM only’ strategy, the ICER for RUSF only exceeded Mali’s 
GDP per capita if the average recovery time exceeded 8.8 
weeks, more than twice the average recovery time observed 
in the trial (figure 3). The probability of developing SAM 
among untreated MAM cases was also highly influential; 
higher probabilities of developing SAM corresponded to 
more favourable cost-effectiveness ratios for RUSF treat-
ment due to the increased probability of averting incident 
SAM with RUSF treatment.
The decision to provide treatment depended on the will-
ingness-to-pay threshold, with the ‘Treat SAM only’ strategy 
cost-effective at willingness-to-pay values between US$142 
and US$347 per DALY averted and providing RUSF treat-
ment for MAM becoming cost-effective at willingness-to-pay 
values greater than US$347 (figure 4).
dIsCussIon
Using primary data from a recent cluster randomised trial 
combined with estimates from secondary published data, 
our results show that providing MAM treatment is cost-ef-
fective across a wide range of cost-effectiveness thresholds. 
Despite having the highest per-unit food costs, we found 
that RUSF was the optimal supplement for MAM treatment 
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Figure 2 Cost-effectiveness acceptability curves for competing treatment strategies, using DALY averted as the outcome. 
CSB, corn–soy blend; DALY, disability-adjusted life year; GDP, gross domestic product; ICER, incremental cost-effectiveness 
ratio; LMF, locally milled flour; MI, Misola; RUSF, ready-to-use supplementary food; SAM, severe acute malnutrition.
Figure 3 Tornado diagram of one-way sensitivity analyses on key model parameters. Parameters that changed the ICER by 
less than US$10 were excluded from the figure. DALY, disability-adjusted life year; ICER, incremental cost-effectiveness ratio; 
MAM, moderate acute malnutrition; RUSF, ready-to-use supplementary food; SAM, moderate acute malnutrition.
when compared with three other supplementary food 
options.
Several studies have reported the effectiveness of 
individual dietary supplements for the treatment of 
MAM,8 9 12 22 but our results also provide evidence on the 
cost-effectiveness of MAM treatment. There is no universal 
definition of a threshold ratio below which an intervention 
is considered cost-effective, but WHO has suggested that 
interventions with cost-effectiveness ratios <1 times per 
capita GDP per DALY averted for a given country (US$732 
8 Isanaka S, et al. BMJ Glob Health 2019;4:e001227. doi:10.1136/bmjgh-2018-001227
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Figure 4 Cost-effectiveness plane (incremental cost per DALY averted) comparing ‘do nothing,’ ‘treat SAM only,’ and 4 MAM 
treatment strategies. CSB, corn–soy blend; DALY, disability-adjusted life year; LMF, locally milled flour; MI, Misola; RUSF, 
ready-to-use supplementary food; SAM, severe acute malnutrition.
in Mali) be considered ‘very cost-effective’ and <3 times per 
capita GDP per DALY averted (US$2196 in Mali) be consid-
ered ‘cost-effective’.19 With an estimated cost of US$338 
per DALY averted, RUSF treatment for MAM could be 
considered very cost-effective in this setting. The CSB++, 
MI and LMF supplements were dominated in this analysis 
by RUSF, but the ICER for these strategies compared with 
‘Treat SAM only’ were favourable and ranged from US$446 
to US$630, suggesting that in situations where RUSF were 
unavailable or there were other reasons to prefer these 
alternatives, they would also be very cost-effective.
Overall, despite the relatively small gain in absolute 
survival estimated from our trial and secondary data, 
community-based MAM treatment has the potential to 
avert a high number of deaths due to the large burden of 
MAM. If the mortality reduction estimated in our analysis 
(0.55% for RUSF) is applied to the population of children 
under 5 with MAM (330 000 in Mali and 34.1 million glob-
ally) then providing MAM treatment in addition to SAM 
treatment would avert over 1800 deaths in Mali and 187 
000 deaths globally each year.1 23 MAM treatment also 
maintains a favourable cost-effectiveness ratio due to its 
low overall costs. The cost-effectiveness of this intervention 
compares favourably with other basic health interventions 
that are generally considered to be cost-effective, such as 
the provision of oral rehydration solution for the manage-
ment of diarrhoea (ICER=US$150 per DALY averted), 
intrapartum care (ICER=US$200–500 per DALY averted) 
and treating obstructed labour with Caesarean delivery 
(ICER=US$1600–2600 per DALY averted).24 Sensitivity 
analyses (figure 3) suggest MAM treatment would remain 
very cost-effective even at reduced effectiveness or greater 
food costs. Decreasing treatment delivery costs through 
integration with routine health services or achieving econ-
omies of scale with higher coverage and/or more cases 
treated may further improve the cost-effectiveness of MAM 
treatment.
Supplementary foods, personnel and infrastructure each 
contributed an important proportion to total MAM treat-
ment costs, but none materially influenced conclusions 
regarding the overall cost-effectiveness of MAM treatment. 
Community-based screening, which has the potential to 
promote early case finding and increase treatment refer-
rals,25 represented a relatively small sum in the management 
of acute malnutrition. Greater investment in increasing 
screening frequency or improving screening efficiencies, 
such as through increased community mobilisation, could 
increase programme coverage, reduce per-capita fixed 
costs associated with treatment and prevent the more costly 
management of complicated cases.
The decision tree model synthesised multiple data 
sources, and we accounted for uncertainty in each of these 
data sources using probabilistic sensitivity analysis (tables 1 
and 2). Additional one-way sensitivity analysis (figure 3) 
showed that results were most sensitive to assumptions 
about average time to recovery in the RUSF arm (4.3 weeks 
in the parent trial and base case) and progression to SAM 
without treatment (9.3% in the base case). In our model, 
longer times to recovery correspond to both increased 
costs of MAM treatment as well as increased probability 
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of mortality as children remained in the hazardous MAM 
condition for a longer period. Sensitivity analyses suggest 
that even assuming a 8.8-week time to recovery, the cost 
per DALY averted by RUSF treatment would remain highly 
cost-effective. Data from additional effectiveness studies—
which vary the quantity of supplement given, duration of 
treatment or discharge criteria in varied and programmatic 
settings—can provide more evidence on the expected clin-
ical effectiveness of dietary supplements and would be 
valuable to resolve uncertainty for more precise cost-effec-
tiveness estimates. Food costs had relatively little impact on 
the cost-effectiveness of MAM treatment overall but were 
influential in the choice between MAM dietary supple-
ments (RUSF vs CSB++, results not shown).
We found providing SAM treatment only to be highly 
cost-effective (ICER=US$3974 per death averted and 
US$142 per DALY averted). This finding is consistent with 
previous reports from African settings suggesting commu-
nity-based SAM treatment is cost-effective, relative to no 
SAM treatment. These earlier studies (from 2007 to 2008) 
reported cost-effectiveness ratios of US$1365–1760 per 
death averted and US$42–53 per DALY averted,26 27 lower 
than estimated in our study, reflecting differences in price 
levels and in assumptions regarding the mortality risk of 
untreated SAM. Our study adds evidence to suggest that 
expanding services to provide treatment for both MAM 
and SAM is a cost-effective extension of SAM services at a 
willingness-to-pay value above US$347 per DALY averted.
This study setting in Mali supported high recovery and 
low mortality, and is likely to have reduced the observed 
progression to SAM, hospitalisation and death. The health 
system provides a basic package of health services, which 
would be similar to that provided in other resource-con-
strained settings at the primary care level. Overall, the bene-
fits of MAM treatment in Mali can likely be generalised to 
similar contexts in sub-Saharan Africa, although contextual 
factors, such as SAM burden, programme effectiveness and 
coverage and supplement utilisation within the household, 
may affect the degree to which the results can be directly 
extrapolated.
This analysis has several limitations. First, participant 
recruitment, clinical management and costs in the parent 
trial may differ from programmatic settings. In this anal-
ysis, we assumed clinical outcomes observed in the parent 
trial could be maintained in programmatic settings. While 
cost variables were also extrapolated from the trial setting, 
we were able to omit costs of protocol-driven procedures 
that would not be relevant in routine programme settings, 
including the cost of study-specific personnel, the cost of 
data management and the cost of follow-up after recovery. 
Further studies conducted in the context of ongoing 
programmes should be used to inform and update these 
parameters; effectiveness and food costs may vary across 
settings and be a source of uncertainty. Second, in building 
the model, we assumed that differences in health effects 
and costs would be realised in the 12 months following 
initial presentation, and that there would be no difference 
in cost or survival among children alive at the end of this 
period. It is plausible that children who recover under 
MAM treatment could be at higher risk of poor future 
health, related to having experienced MAM, but evidence 
on long-term consequences is lacking. Third, we did not 
include household costs associated with MAM treatment. 
A societal perspective would have allowed for the most 
inclusive perspective possible, incorporating the potential 
benefits, harms and costs for all parties involved. Including 
household costs associated with lost productivity among 
caregivers due to supplement preparation and clinic visit 
attendance in this analysis would have likely strengthened 
the cost-effectiveness of RUSF relative to other dietary 
supplements, which require cooking and potentially 
longer duration of treatment. Finally, to make results most 
relevant to real-world decisions, we focused on a narrow set 
of dietary supplements. New programmes that harmonise 
the treatment of MAM and SAM with therapeutic foods 
at variable doses have been field-tested.28 As the absolute 
resources required to treat MAM would be substantial due 
to the large burden, strategies that focus on prevention of 
MAM should also be considered to reduce treatment case-
loads and absolute programme costs.
ConClusIon
Cost-effectiveness analysis may be used to inform national 
and international decision-making and to direct resources 
towards interventions with the greatest potential to improve 
child health. MAM is associated with a large proportion of 
the burden of child morbidity and mortality, but appro-
priate treatment can both reduce the duration of a MAM 
episode and the risk of progression to SAM. The potential 
public health impact of treating MAM is therefore great. 
Our findings suggest that MAM treatment is a cost-effec-
tive extension of existing SAM services across a range of 
willingness-to-pay thresholds and has the potential to be a 
promising public health investment in settings with avail-
able resources.
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